euro adhoc: Intercell AG / Joint Ventures/Cooperation/Collaboration / Intercell AG and CSL Ltd. sign Exclusive Agreement for Marketing and Distribution of Japanese Encephalitis Vaccine (E)

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

30.08.2005

Vienna, Austria, August 30, 2005 - Intercell AG announced today the signature of
an exclusive agreement with CSL Ltd. for the Marketing and Distribution of
Intercell´s novel cell culture based Japanese encephalitis vaccine in Australia.
It is Intercell’s first commercialization agreement for the future delivery of
its lead vaccine product which is planned to enter Phase III clinical trials in
September 2005.

In order to optimally market the vaccine in Australia where the disease is
endemic, Intercell has been seeking for a strong local strategic partner. Under
the terms of this agreement CSL Ltd. receives the sole and exclusive marketing
and distribution rights of Intercell´s novel prophylactic vaccine against
Japanese encephalitis in Australia, New Zealand, Papua New Guinea and Pacific
Islands.

Intercell is planning to market the product independently from this agreement
with CSL Ltd. in the United States and Europe targeting the travelers and armed
forces market to replace current suboptimal vaccines produced on mouse brain.

The production of the vaccine will be performed at Intercell´s state-of-the-art
vaccine manufacturing facility in Livingston, Scotland.

"This agreement with the leading vaccine company in Australia is another
important step forward in our global marketing and commercialization strategy
for this modern cell culture based Japanese Encephalitis vaccine", states Gerd
Zettlmeissl, COO Intercell AG. "It proves our vaccine to be highly attractive
for marketing and distribution and further substantiates our business strategy
to generate significant future revenues through product sales."

About Intercell’s JE vaccine
Intercell´s novel Japanese Encephalitis vaccine is a purified, inactivated
vaccine for active immunization of adults against the Japanese Encephalitis
virus and has successfully concluded Phase II clinical trials.
In a Phase II head-to-head comparison with JE-VAX®, Intercell’s vaccine was
shown to be:
» Less reactogenic - both in frequency and intensity
» More potent - higher antibody levels at all doses studied one month after
the immunizations; this vaccine also showed high seroconversion rates one
month after a single dose
» More convenient - 2 doses versus 3 doses and liquid versus freeze-dried
format
» More persistent - higher persistence of antibodies two years after primary
immunization

More detailed Phase II results were presented at the 53rd annual meeting of the
American Society of Tropical Medicine and Hygiene, Nov 7th - Nov 11th 2004 in
Miami.

About CSL
CSL Limited is a global, specialty biopharmaceutical company that develops,
manufactures and markets products to treat and prevent serious human medical
conditions; Headquartered in Melbourne Australia, the CSL Group includes CSL
Bioplasma, CSL Pharmaceutical and ZLB Behring incorporating ZLB Plasma Services;
CSL has over 7,000 employees working in 25 countries, with major facilities in
Australia, Germany, Switzerland, US and Japan; CSL's Pharmaceutical Division
develops, manufactures and markets vaccines for human use. The Division markets
a comprehensive range of Children’s vaccines, Travel Vaccines, Respiratory
Vaccines Adult Vaccines and Antivenoms; and, the Division also markets
Antibiotics, Dermatological Products, Emergency Products, Neurological Products,
Analgesic Products, and Urological Products supplied by other manufacturers.
For more information please visit www.csl.com.au

About Intercell
Intercell AG is a fast growing biotechnology company with a clear strategy and
focus on the design and development of novel vaccines for prophylaxis and
treatment of diseases with substantial unaddressed medical need. The Company’s
unique position is based on the combination of antigens and immunizers
(adjuvants) derived from its proprietary technology platforms and its in-house
GMP manufacturing facilities. Intercell’s technology has been endorsed by
collaborative agreements with a number of global pharmaceutical companies,
including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum
Institut. The Company has a broad development pipeline with a vaccine for
Japanese Encephalitis about to enter Phase III, a vaccine for Hepatitis C
undergoing Phase II trials, and five products focused on infectious diseases in
the pre-clinical phase. Intercell is listed on the Vienna stock exchange under
the symbol "ICLL".
For more information please visit: www.intercell.com

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

end of announcement euro adhoc 30.08.2005 07:53:19
--------------------------------------------------------------------------------

emitter: Intercell AG
Campus Vienna Biocenter 6
A-1030 Wien
phone: +43 1 20620-0
FAX: +43 1 20620-800
mail: investors@intercell.com
WWW: www.intercell.com
ISIN: AT0000612601
indexes:
stockmarkets:
sector: Biotechnology
language: English

OTS-ORIGINALTEXT UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS | OTB

print